Intra-Cellular Therapies Total Current Liabilities

Intra-Cellular Therapies (ITCI) currently reports a total current liabilities of $210M as of December 2024. That compares with $120M in the prior-year period — up 66.5% year over year. Use the charts on this page to explore Intra-Cellular Therapies's total current liabilities history and peer comparisons.

Intra-Cellular Therapies's total current liabilities increased from $120M to $210M — a 66.5% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intra-Cellular Therapies reported $210M in total current liabilities as of December 2024. That compares with $120M in the prior-year period — up 66.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $210M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intra-Cellular Therapies, and consider following ITCI for alerts when major investors trade the stock.

Intra-Cellular Therapies is classified in the Healthcare sector. On total current liabilities, it currently shows $210M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ITCI with unrelated industries.